Altered Angiogenic Growth Factors in Urine of Prostate Cancer Survivors With Radiation History and Radiation Cystitis

Urology. 2018 Oct:120:180-186. doi: 10.1016/j.urology.2018.07.025. Epub 2018 Jul 29.

Abstract

Objective: To determine if the vascular damage in bladders of prostate cancer (PCa) survivors with radiation cystitis can be detected through altered angiogenic growth factors in urine.

Methods: Urine samples from PCa survivors with a history of external beam radiation therapy were tested for a panel of angiogenic growth factors by Luminex assay. Urine creatinine levels were measured through high performance liquid chromatography. Through a patient survey, data on patient demographics, radiation history, and urinary symptoms were collected.

Results: Hepatocyte growth factor (HGF), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) were altered in urine of PCa survivors with a history of radiation therapy. HGF and PlGF were elevated in response to irradiation, while VEGF had a decreasing trend. Within the irradiated population, HGF was also increased in patients diagnosed with radiation cystitis and patients with hematuria. PlGF and VEGF were only increased in the first year postirradiation, and VEGF was elevated in patients with hematuria. Finally, creatinine levels were increased in PCa survivors with a history of radiation therapy.

Conclusion: Radiation cystitis is a debilitating bladder condition that cancer survivors are at risk of developing after pelvic radiation. In this study, we identified 3 pro-angiogenic factors that may be urine biomarkers and, if validated in future studies, could indicate new strategy approaches to treat radiation cystitis.

MeSH terms

  • Aged
  • Biomarkers / urine
  • Cancer Survivors
  • Case-Control Studies
  • Creatinine / urine
  • Cystitis / etiology*
  • Cystitis / urine
  • Hematuria / etiology
  • Hepatocyte Growth Factor / urine*
  • Humans
  • Male
  • Placenta Growth Factor / urine*
  • Prostatic Neoplasms / radiotherapy
  • Radiotherapy / adverse effects*
  • Vascular Endothelial Growth Factor A / urine*

Substances

  • Biomarkers
  • Vascular Endothelial Growth Factor A
  • Placenta Growth Factor
  • Hepatocyte Growth Factor
  • Creatinine